Oct. 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California.
|
Scooped by
TEAM Mike Lopez Memorial Foundation |Find us on Twitter:@TEAMCUREALS
onto #ALS AWARENESS #LouGehrigsDisease #PARKINSONS October 22, 2017 9:20 PM
|